Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8290147 | 0.81 | KEAP1 (0.56) | CYP2A6KEAP1NFE2L2MAPTCA2 | |
| SCHEMBL8290149 | 0.80 | CYP2A6 (0.56) | CYP2A6KEAP1NFE2L2MAPTCA2 | |
| SCHEMBL10901085 | 0.79 | NR4A2 (0.52) | CYP2A6KEAP1NFE2L2MAPTCMA1 | |
| SCHEMBL2650447 | 0.78 | KEAP1 (0.59) | CYP2A6KEAP1NFE2L2MAPTCA2 | |
| SCHEMBL3180015 | 0.76 | KEAP1 (0.54) | CYP2A6KEAP1NFE2L2MAPTCA2 | |
| SCHEMBL10197927 | 0.76 | CMA1 (0.61) | MAPTMAOBCMA1PKM | |
| SCHEMBL7495653 | 0.76 | KEAP1 (0.54) | CYP2A6KEAP1NFE2L2MAPTCA2 | |
| SCHEMBL7498066 | 0.73 | CYP2A6 (0.49) | CYP2A6KEAP1NFE2L2MAPTCA2 | |
| SCHEMBL8554891 | 0.73 | KEAP1 (0.54) | CYP2A6KEAP1NFE2L2MAPTCA2 | |
| SCHEMBL10978845 | 0.72 | CYP2A6 (0.44) | CYP2A6KEAP1NFE2L2MAPTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546358-B2 | Method of treating asthma | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-01 | — | — | US | disclosed |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | HAWKINS MICHAEL J (US) | 2012-01-26 | — | — | US | disclosed |
| US-20100048513-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2010-02-25 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048513-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CYP2A6 1090/4885KEAP1 466/4885NFE2L2 3735/4885 |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | CMA1, SERPINB1, TPSAB1 | CYP2A6 1090/4885KEAP1 466/4885NFE2L2 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.